138 related articles for article (PubMed ID: 36730552)
1. A case of lung adenocarcinoma with MET∆ex14 mutation regressed after preoperative treatment with savolitinib, and successfully underwent radical resection.
Yang F; Chen QF
Anticancer Drugs; 2023 Feb; 34(2):302-305. PubMed ID: 36730552
[TBL] [Abstract][Full Text] [Related]
2. A durable response to savolitinib in a patient with lung adenocarcinoma harboring two novel MET exon 14 skipping sites.
Gu L; Zhao Y; Wen F; Zhang D; Cai J; Chen Z
Anticancer Drugs; 2023 Sep; 34(8):949-953. PubMed ID: 36846984
[TBL] [Abstract][Full Text] [Related]
3. The safety and feasibility of preoperative induction therapy of Savolitinib in non-small cell lung cancer patients with MET exon 14 skipping mutation.
Deng HY; Qiu XM; Zhu DX; Tang XJ; Zhou Q
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4623-4628. PubMed ID: 36171456
[TBL] [Abstract][Full Text] [Related]
4. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.
Lu S; Fang J; Li X; Cao L; Zhou J; Guo Q; Liang Z; Cheng Y; Jiang L; Yang N; Han Z; Shi J; Chen Y; Xu H; Zhang H; Chen G; Ma R; Sun S; Fan Y; Li J; Luo X; Wang L; Ren Y; Su W
Lancet Respir Med; 2021 Oct; 9(10):1154-1164. PubMed ID: 34166627
[TBL] [Abstract][Full Text] [Related]
5. Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review.
Tian J; Lin Z; Chen Y; Fu Y; Ding Z
Front Oncol; 2022; 12():1006634. PubMed ID: 36387081
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant savolitinib targeted therapy for stage IIIB-N3 lung adenocarcinoma harboring mesenchymal-epithelial transition exon 14 skipping mutation: a case report and literature review.
Chen L; Chen JF; He JT; Rong H; Zhuang X; Peng J
Anticancer Drugs; 2024 Jun; 35(5):445-449. PubMed ID: 38385995
[TBL] [Abstract][Full Text] [Related]
7. Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer.
Miao K; Zhang X; Wang H; Si X; Zhang L
Thorac Cancer; 2023 May; 14(13):1162-1170. PubMed ID: 36944506
[TBL] [Abstract][Full Text] [Related]
8. Landscape of Savolitinib Development for the Treatment of Non-Small Cell Lung Cancer with MET Alteration-A Narrative Review.
Zhu X; Lu Y; Lu S
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551608
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring
Yu Y; Ren Y; Fang J; Cao L; Liang Z; Guo Q; Han S; Ji Z; Wang Y; Sun Y; Chen Y; Li X; Xu H; Zhou J; Jiang L; Cheng Y; Han Z; Shi J; Chen G; Ma R; Fan Y; Sun S; Jiao L; Jia X; Wang L; Lu P; Xu Q; Luo X; Su W; Lu S
Ther Adv Med Oncol; 2022; 14():17588359221133546. PubMed ID: 36339926
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
[TBL] [Abstract][Full Text] [Related]
11. Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.
Wang SXY; Zhang BM; Wakelee HA; Koontz MZ; Pan M; Diehn M; Kunder CA; Neal JW
Anticancer Drugs; 2019 Jun; 30(5):537-541. PubMed ID: 30762593
[TBL] [Abstract][Full Text] [Related]
12. Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
Cortot A; Le X; Smit E; Viteri S; Kato T; Sakai H; Park K; Camidge DR; Berghoff K; Vlassak S; Paik PK
Clin Lung Cancer; 2022 May; 23(3):195-207. PubMed ID: 35272955
[TBL] [Abstract][Full Text] [Related]
13. MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values.
Lee GD; Lee SE; Oh DY; Yu DB; Jeong HM; Kim J; Hong S; Jung HS; Oh E; Song JY; Lee MS; Kim M; Jung K; Kim J; Shin YK; Choi YL; Kim HR
J Thorac Oncol; 2017 Aug; 12(8):1233-1246. PubMed ID: 28502721
[TBL] [Abstract][Full Text] [Related]
14. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
15. Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer.
Watari N; Yamaguchi K; Terada H; Hamai K; Masuda K; Nishimura Y; Sakamoto S; Masuda T; Horimasu Y; Miyamoto S; Nakashima T; Iwamoto H; Shoda H; Ishikawa N; Fujitaka K; Miyazaki K; Miyata Y; Hamada H; Awai K; Hattori N
BMC Pulm Med; 2022 Jun; 22(1):260. PubMed ID: 35773658
[TBL] [Abstract][Full Text] [Related]
16. Detection of
Subramanian J; Tawfik O
Expert Rev Anticancer Ther; 2021 Aug; 21(8):877-886. PubMed ID: 33957836
[No Abstract] [Full Text] [Related]
17. Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring
Fu M; Feng CM; Xia DQ; Ji ZM; Xia HL; Hu NN; Leng ZJ; Xie W; Fang Y; Cao LJ; Zhang JQ
Front Oncol; 2022; 12():954886. PubMed ID: 36052259
[No Abstract] [Full Text] [Related]
18. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
[TBL] [Abstract][Full Text] [Related]
19. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.
Choi W; Park SY; Lee Y; Lim KY; Park M; Lee GK; Han JY
Cancer Res Treat; 2021 Oct; 53(4):1024-1032. PubMed ID: 33540494
[TBL] [Abstract][Full Text] [Related]
20. Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib.
Li J; Feng Y; Tan Y; Duan Q; Zhang Q
Front Oncol; 2022; 12():863560. PubMed ID: 35444936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
